Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in PLoS One Retrieve available abstracts of 206 articles: HTML format

Single Articles

January 2025
1. KANG SJ, Park J, Choi GS, Kim JG, et al
   Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.
   PLoS One. 2025;20:e0313438.
   PubMed     Abstract available
   
   
   
2. MAMUDU L, Sulley S, Atandoh PH, Reyes JL, et al
   Disparities in time to treatment initiation of invasive lung cancer among Black and White patients in Tennessee.
   PLoS One. 2025;20:e0311186.
   PubMed     Abstract available
   
   
   
3. CHEN X, Kanhar GM, Hu S, Wu C, et al
   Occult metastases and survival of lung cancer by clinical diagnosis and CT screening: A simulation study.
   PLoS One. 2025;20:e0313544.
   PubMed     Abstract available
   
   
   
4. HUANG T, Ma K, Wang Y
   Characterization and evaluation of the cytotoxic, antioxidant, and anti-human lung cancer properties of copper nanoparticles green-synthesized by fennel extract following the PI3K/AKT/Mtor signaling pathway.
   PLoS One. 2025;20:e0309207.
   PubMed     Abstract available
   
   
   
5. SOBOLEVA A, Kaznatcheev A, Cavill R, Schneider K, et al
   Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data.
   PLoS One. 2025;20:e0310844.
   PubMed     Abstract available
   
   
   
6. SULLIVAN FM, Mair FS, Anderson W, Chew C, et al
   Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.
   PLoS One. 2025;20:e0306163.
   PubMed     Abstract available
   
   
   
7. GWON HR, Woo A, Yong SH, Park YM, et al
   Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm.
   PLoS One. 2025;20:e0315898.
   PubMed     Abstract available
   
   
   
8. ABDULLAH S, Altwaijry N, Alnakhli M, ALenezi G, et al
   Novel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency.
   PLoS One. 2025;20:e0314941.
   PubMed     Abstract available
   
   
   
9. ANOSOVA O, Head A, Collins B, Alexiou A, et al
   Estimating the burden of underdiagnosis within England: A modelling study of linked primary care data.
   PLoS One. 2025;20:e0313877.
   PubMed     Abstract available
   
   
   
10. AFZAL M, Abusalah MAHA, Shehzadi N, Absar M, et al
    Investigation of biometabolites and novel antimicrobial peptides derived from promising source Cordyceps militaris and effect of non-small cell lung cancer genes computationally.
    PLoS One. 2025;20:e0310103.
    PubMed     Abstract available
    
    
    
11. ZAPATA DONGO RJ, Fontana D, Mologni L, Faya Castillo JE, et al
    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.
    PLoS One. 2025;20:e0308747.
    PubMed     Abstract available
    
    
    
12. WANG Q, Luo Y, Zhao Y, Wang S, et al
    Automated recognition and segmentation of lung cancer cytological images based on deep learning.
    PLoS One. 2025;20:e0317996.
    PubMed     Abstract available
    
    
    
13. JAHAN F, Haque S, Hogg J, Price A, et al
    Assessing the influence of the modifiable areal unit problem on Bayesian disease mapping in Queensland, Australia.
    PLoS One. 2025;20:e0313079.
    PubMed     Abstract available
    
    
    
14. PRAKAIKIETIKUL P, Tajarenmuang P, Losuriya P, Ina N, et al
    Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.
    PLoS One. 2025;20:e0313577.
    PubMed     Abstract available
    
    
    
15. ZHU Q, Fei L
    Cross-ViT based benign and malignant classification of pulmonary nodules.
    PLoS One. 2025;20:e0318670.
    PubMed     Abstract available
    
    
    
16. SHAO K, Du F, Qiu L, Zhang Y, et al
    Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.
    PLoS One. 2025;20:e0318462.
    PubMed     Abstract available
    
    
    
17. BARBEAU LMO, Beelen NA, Savelkouls KG, Keulers TGH, et al
    MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0316716.
    PubMed     Abstract available
    
    
    
18. RABBY MS, Islam MM, Kumar S, Maniruzzaman M, et al
    Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches.
    PLoS One. 2025;20:e0317296.
    PubMed     Abstract available
    
    
    
19. KHAN MA, Khan ZA, Husain I, Upadhyay S, et al
    Effects of pressure on the survival and viability of cancer cells in vitro: An analytical study.
    PLoS One. 2025;20:e0311685.
    PubMed     Abstract available
    
    
    
20. HIGASHI S, Yamakuchi M, Hashinokuchi H, Takenouchi K, et al
    Adaptation to acidic conditions that mimic the tumor microenvironment, downregulates miR-193b-3p, and induces EMT via TGFbeta2 in A549 cells.
    PLoS One. 2025;20:e0318811.
    PubMed     Abstract available
    
    
    
21. DIAO S, Wan Y, Huang D, Huang S, et al
    Optimizing Bi-LSTM networks for improved lung cancer detection accuracy.
    PLoS One. 2025;20:e0316136.
    PubMed     Abstract available
    
    
    
22. PAN X, Togka K, Ten Berge H, de Jong L, et al
    Lung cancer screening with volume computed tomography is cost-effective in Greece.
    PLoS One. 2025;20:e0316351.
    PubMed     Abstract available
    
    
    
23. GHIROTTO L, Paci E, Bricci C, Marini S, et al
    Self-blaming as a barrier to lung cancer screening and smoking cessation programs in Italy. A qualitative study.
    PLoS One. 2025;20:e0318732.
    PubMed     Abstract available
    
    
    
24. 
    Retraction: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer.
    PLoS One. 2025;20:e0320171.
    PubMed    
    
    
    
25. TANG S, Bao Q, Ji Q, Wang T, et al
    Improvement of RT-DETR model for ground glass pulmonary nodule detection.
    PLoS One. 2025;20:e0317114.
    PubMed     Abstract available
    
    
    
26. ALLEN J, Healey G, Macdonald I
    Lung cancer associated autoantibody responses are detectable years before clinical presentation.
    PLoS One. 2025;20:e0315220.
    PubMed     Abstract available
    
    
    
27. LV Z, Liu P, Yang Y, Ji J, et al
    Correction: (-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2alpha/ATF4 signaling pathway.
    PLoS One. 2025;20:e0320174.
    PubMed     Abstract available
    
    
    
28. HOSSAIN MS, Basak N, Mollah MA, Nahiduzzaman M, et al
    Ensemble-based multiclass lung cancer classification using hybrid CNN-SVD feature extraction and selection method.
    PLoS One. 2025;20:e0318219.
    PubMed     Abstract available
    
    
    
29. LI C, Zhong S, Chen J, Mu X, et al
    TsRNA-49-73-Glu-CTC: A promising serum biomarker in non-small cell lung cancer.
    PLoS One. 2025;20:e0320187.
    PubMed     Abstract available
    
    
    
30. ZHANG DT, Shi GX, Jia JY, Tan FW, et al
    Electroacupuncture for acute postoperative pain during coughing after video-assisted thoracoscopic surgery: study protocol for a pilot randomized controlled trial.
    PLoS One. 2025;20:e0316698.
    PubMed     Abstract available
    
    
    
31. ZHENG Z, Zhu H, Fang L
    Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.
    PLoS One. 2025;20:e0320189.
    PubMed     Abstract available
    
    
    
32. 
    Correction: Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.
    PLoS One. 2025;20:e0321150.
    PubMed     Abstract available
    
    
    
33. JAVRUSHYAN H, Ginovyan M, Harutyunyan T, Gevorgyan S, et al
    Elucidating the impact of Hypericum alpestre extract and L-NAME on the PI3K/Akt signaling pathway in A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cells.
    PLoS One. 2025;20:e0303736.
    PubMed     Abstract available
    
    
    
34. WANG M, Jiang W, Wei T, Li Z, et al
    Dynamic changes and metabolic function of intestinal flora in patients with postoperative pneumonia after lung cancer surgery.
    PLoS One. 2025;20:e0321016.
    PubMed     Abstract available
    
    
    
35. KIM MS, Kim MS
    Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells.
    PLoS One. 2025;20:e0320668.
    PubMed     Abstract available
    
    
    
36. HAO L, Zhang J, Di Y, Qi Z, et al
    Predicting a failure of postoperative thromboprophylaxis in non-small cell lung cancer: A stacking machine learning approach.
    PLoS One. 2025;20:e0320674.
    PubMed     Abstract available
    
    
    
37. EL-TANANI M, Satyam SM, Rabbani SA, Obeidat RM, et al
    Decoding oncogenic secrets of regulator of chromosome condensation 1: A breakthrough mechanistic evidence from breast and lung cancer models.
    PLoS One. 2025;20:e0319748.
    PubMed     Abstract available
    
    
    
38. PRAKAIKIETIKUL P, Wannasopha Y, Euathrongchit J, Tantraworasin A, et al
    CT features and histogram analysis of non-contrast images for differentiating malignant and benign mediastinal lymph nodes in Non-Small Cell Lung Cancer (NSCLC).
    PLoS One. 2025;20:e0321921.
    PubMed     Abstract available
    
    
    
39. GAO C, Liu M, Sun Y, Zhao Z, et al
    Association between advanced lung cancer inflammation index and gallstone prevalence among U.S. adults: A population-based study.
    PLoS One. 2025;20:e0321733.
    PubMed     Abstract available
    
    
    
40. KUO P, Elboudwarej E, Zavodovskaya M, Lin KW, et al
    Trop-2 expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0321555.
    PubMed     Abstract available
    
    
    
41. PONGPIACHAN S, Tipmanee D, Khumsup C, Hirunyatrakul P, et al
    Size-segregated analysis of PAHs in Urban air: Source apportionment and health risk assessment in an Urban canal-adjacent environment.
    PLoS One. 2025;20:e0320405.
    PubMed     Abstract available
    
    
    
42. MALIK V, Mittal R, Gupta D, Juneja S, et al
    Optimizing chemotherapeutic targets in non-small cell lung cancer with transfer learning for precision medicine.
    PLoS One. 2025;20:e0319499.
    PubMed     Abstract available
    
    
    
43. YU W, Long L, Hou Q, Yi B, et al
    Development of a nomogram for overall survival prediction in primary upper lobe lung cancer patients: A SEER population-based analysis.
    PLoS One. 2025;20:e0321955.
    PubMed     Abstract available
    
    
    
44. MOUSAVI SF, Masoudi S, Rezaei N, Pourghazi F, et al
    Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study.
    PLoS One. 2025;20:e0320931.
    PubMed     Abstract available
    
    
    
45. DE-TORRES JP, Giron-Flamenco JJ, Rodriguez M, de la Fuente-Ano A, et al
    Exploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program.
    PLoS One. 2025;20:e0320704.
    PubMed     Abstract available
    
    
    
46. OTERO-CARRASCO B, Nevado PT, Munoz RA, Ferreiro GD, et al
    Finding patterns in lung cancer protein sequences for drug repurposing.
    PLoS One. 2025;20:e0322546.
    PubMed     Abstract available
    
    
    
47. RAO S, Wu H, Zhang G, Dong W, et al
    A comparative analysis of the burden, trends and inequalities of tracheal, bronchus, and lung cancer in India from 2000 to 2021: A systematic analysis for the Global Burden of Disease study 2021.
    PLoS One. 2025;20:e0322646.
    PubMed     Abstract available
    
    
    
48. SALOMONSSON A, Ehinger D, Jonsson M, Botling J, et al
    Gene expression-based identification of prognostic markers in lung adenocarcinoma.
    PLoS One. 2025;20:e0310232.
    PubMed     Abstract available
    
    
    
49. LI Z, Zhu Z, Wang P, Hou C, et al
    Diagnostic, prognostic, and immunological roles of FUT8 in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2025;20:e0321756.
    PubMed     Abstract available
    
    
    
50. YIN X, Liang HW, Liu Y, Huang W, et al
    Lobectomy versus sublobar resection on survival in patients with stage T1-2N0M0 small cell lung cancer.
    PLoS One. 2025;20:e0324315.
    PubMed     Abstract available
    
    
    
51. 
    Retraction: Efficient lung cancer detection using computational intelligence and ensemble learning.
    PLoS One. 2025;20:e0324356.
    PubMed    
    
    
    
52. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed     Abstract available
    
    
    
53. PEREZ AL, Zamora M, Bahena M, Aramburo-Williams R, et al
    The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability.
    PLoS One. 2025;20:e0316983.
    PubMed     Abstract available
    
    
    
54. ZHANG Y, Hu Y, Xi J, Wu B, et al
    Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
    PLoS One. 2025;20:e0319357.
    PubMed     Abstract available
    
    
    
55. JIM JR, Rayed ME, Mridha MF, Nur K, et al
    XLLC-Net: A lightweight and explainable CNN for accurate lung cancer classification using histopathological images.
    PLoS One. 2025;20:e0322488.
    PubMed     Abstract available
    
    
    
56. ZHENG Z, Zhu H, Fang L
    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
    PLoS One. 2025;20:e0325171.
    PubMed     Abstract available
    
    
    
57. WANG X, Sharpnack J, Lee TCM
    Improving lung cancer diagnosis and survival prediction with deep learning and CT imaging.
    PLoS One. 2025;20:e0323174.
    PubMed     Abstract available
    
    
    
58. ABUMANSOUR H, Abusara OH, Abu-Sini M, Khalil W, et al
    Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells.
    PLoS One. 2025;20:e0324930.
    PubMed     Abstract available
    
    
    January 2024
59. ZHANG J, Huang X, Liu Y, Han Y, et al
    GAN-based medical image small region forgery detection via a two-stage cascade framework.
    PLoS One. 2024;19:e0290303.
    PubMed     Abstract available
    
    
    
60. GAO X, Tang M, Tian S, Li J, et al
    ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis.
    PLoS One. 2024;19:e0296829.
    PubMed     Abstract available
    
    
    
61. 
    Expression of Concern: Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer.
    PLoS One. 2024;19:e0298436.
    PubMed    
    
    
    
62. KANG J, Zhang J, Tian Z, Xu Y, et al
    The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
    PLoS One. 2024;19:e0276318.
    PubMed     Abstract available
    
    
    
63. FAYA CASTILLO JE, Zapata Dongo RJ, Wong Chero PA, Infante Varillas SF, et al
    Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
    PLoS One. 2024;19:e0295966.
    PubMed     Abstract available
    
    
    
64. 
    Expression of Concern: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2024;19:e0299045.
    PubMed    
    
    
    
65. TIAN P, Du D, Yang L, Zhou N, et al
    SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.
    PLoS One. 2024;19:e0298295.
    PubMed     Abstract available
    
    
    
66. CHEN Q, Li W, Cai N, Chen W, et al
    Comparison of postoperative complications in mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: Protocol for a systematic review and meta-analysis.
    PLoS One. 2024;19:e0298368.
    PubMed     Abstract available
    
    
    
67. MORI S, Ueki Y, Hasegawa M, Nakamura K, et al
    Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
    PLoS One. 2024;19:e0298573.
    PubMed     Abstract available
    
    
    
68. WANG H, Tang H, Yuan S, Liang C, et al
    IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells.
    PLoS One. 2024;19:e0299028.
    PubMed     Abstract available
    
    
    
69. YOO SJ, Park YS, Choi H, Kim DS, et al
    Prospective evaluation of deep learning image reconstruction for Lung-RADS and automatic nodule volumetry on ultralow-dose chest CT.
    PLoS One. 2024;19:e0297390.
    PubMed     Abstract available
    
    
    
70. AJENU EO, Seideneck AM, Pandellapalli E, Shinsky EM, et al
    ABCG2 transporter reduces protein aggregation in cigarette smoke condensate-exposed A549 lung cancer cells.
    PLoS One. 2024;19:e0297661.
    PubMed     Abstract available
    
    
    
71. KESSLER LG, Comstock B, Aiello Bowles EJ, Mou J, et al
    Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design.
    PLoS One. 2024;19:e0297773.
    PubMed     Abstract available
    
    
    
72. AHMAD A, Kulachi MO, Farman M, Junjua MU, et al
    Mathematical modeling and control of lung cancer with IL2 cytokine and anti-PD-L1 inhibitor effects for low immune individuals.
    PLoS One. 2024;19:e0299560.
    PubMed     Abstract available
    
    
    
73. LEE YJ, Kang N, Nam J, Lee EG, et al
    The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea.
    PLoS One. 2024;19:e0299484.
    PubMed     Abstract available
    
    
    
74. MALIK H, Anees T
    Multi-modal deep learning methods for classification of chest diseases using different medical imaging and cough sounds.
    PLoS One. 2024;19:e0296352.
    PubMed     Abstract available
    
    
    
75. XUE Y, Zhang D, Jia L, Yang W, et al
    Integrating image and gene-data with a semi-supervised attention model for prediction of KRAS gene mutation status in non-small cell lung cancer.
    PLoS One. 2024;19:e0297331.
    PubMed     Abstract available
    
    
    
76. MAJUMDER S, Gautam N, Basu A, Sau A, et al
    MENet: A Mitscherlich function based ensemble of CNN models to classify lung cancer using CT scans.
    PLoS One. 2024;19:e0298527.
    PubMed     Abstract available
    
    
    
77. ZHANG L, Xu L, Chen Z, You H, et al
    Risk factors and related miRNA phenotypes of chronic pain after thoracoscopic surgery in lung adenocarcinoma patients.
    PLoS One. 2024;19:e0297742.
    PubMed     Abstract available
    
    
    
78. LI Q, Wei Z, Zhang Y, Zheng C, et al
    Causal role of metabolites in non-small cell lung cancer: Mendelian randomization (MR) study.
    PLoS One. 2024;19:e0300904.
    PubMed     Abstract available
    
    
    
79. MOMOKI Y, Ichinose A, Nakamura K, Iwano S, et al
    Development of automatic generation system for lung nodule finding descriptions.
    PLoS One. 2024;19:e0300325.
    PubMed     Abstract available
    
    
    
80. HAN H, Huang H, Chen AP, Tang Y, et al
    High CASC expression predicts poor prognosis of lung cancer: A systematic review with meta-analysis.
    PLoS One. 2024;19:e0292726.
    PubMed     Abstract available
    
    
    
81. ZHANG Y, Liu H, Chang C, Yin Y, et al
    Machine learning for differentiating lung squamous cell cancer from adenocarcinoma using Clinical-Metabolic characteristics and 18F-FDG PET/CT radiomics.
    PLoS One. 2024;19:e0300170.
    PubMed     Abstract available
    
    
    
82. LV M, Li X, Yin Z, Yang H, et al
    Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
    PLoS One. 2024;19:e0294227.
    PubMed     Abstract available
    
    
    
83. LE ROUX O, Everitt JI, Counter CM
    p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
    PLoS One. 2024;19:e0292189.
    PubMed     Abstract available
    
    
    
84. TRIPLETTE M, Kross EK, Snidarich M, Shahrir S, et al
    An alternating-intervention pilot trial on the impact of an informational handout on patient-reported outcomes and follow-up after lung cancer screening.
    PLoS One. 2024;19:e0300352.
    PubMed     Abstract available
    
    
    
85. MAY T, Clement MS, Halait H, Kohlmann A, et al
    Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
    PLoS One. 2024;19:e0295987.
    PubMed     Abstract available
    
    
    
86. ZHANG H, Cheng X, Guo W, Zheng C, et al
    Metastasis patterns and prognosis in young gastric cancer patients: A propensity score?matched SEER database analysis.
    PLoS One. 2024;19:e0301834.
    PubMed     Abstract available
    
    
    
87. RADWAN AA, Alanazi F, Al-Dhfyan A
    Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
    PLoS One. 2024;19:e0298326.
    PubMed     Abstract available
    
    
    
88. LI H, Huntington S, Gross C, Wang SY, et al
    Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
    PLoS One. 2024;19:e0300789.
    PubMed     Abstract available
    
    
    
89. ZHANG MS, Yeh YC, Huang HN, Lin LW, et al
    The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
    PLoS One. 2024;19:e0301120.
    PubMed     Abstract available
    
    
    
90. KONG Y, Hong L, Xu XC, Chen YF, et al
    The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
    PLoS One. 2024;19:e0301931.
    PubMed     Abstract available
    
    
    
91. WU B, Zhang X, Feng N, Hu Z, et al
    Treatment strategies for stage IA non-small cell lung cancer: A SEER-based population study.
    PLoS One. 2024;19:e0298470.
    PubMed     Abstract available
    
    
    
92. HUH Y, Sohn YJ, Kim HR, Chun H, et al
    Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea.
    PLoS One. 2024;19:e0300389.
    PubMed     Abstract available
    
    
    
93. BAK SH, Park J, Lee S, Kim JH, et al
    Clinical usability of 3D gradient-echo-based ultrashort echo time imaging: Is it enough to facilitate diagnostic decision in real-world practice?
    PLoS One. 2024;19:e0296696.
    PubMed     Abstract available
    
    
    
94. HAN KT, Kim S
    Does improved nurse staffing impact patient outcomes in cancer? Association between chronic diseases and mortality among older adult patients with lung cancer in Korea.
    PLoS One. 2024;19:e0301010.
    PubMed     Abstract available
    
    
    
95. THU YM, Suzawa K, Tomida S, Ochi K, et al
    PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
    PLoS One. 2024;19:e0300644.
    PubMed     Abstract available
    
    
    
96. CHANG GC, Shih JY, Yu CJ, Chao HS, et al
    Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
    PLoS One. 2024;19:e0303046.
    PubMed     Abstract available
    
    
    
97. LEE ACH, Madariaga MLL, Lee SM, Ferguson MK, et al
    The risk analysis index is an independent predictor of outcomes after lung cancer resection.
    PLoS One. 2024;19:e0303281.
    PubMed     Abstract available
    
    
    
98. WANG H, Zhu H, Ding L, Yang K, et al
    Attention pyramid pooling network for artificial diagnosis on pulmonary nodules.
    PLoS One. 2024;19:e0302641.
    PubMed     Abstract available
    
    
    
99. N KACHOUIE N, Deebani W, Shutaywi M, Christiani DC, et al
    Lung cancer clustering by identification of similarities and discrepancies of DNA copy numbers using maximal information coefficient.
    PLoS One. 2024;19:e0301131.
    PubMed     Abstract available
    
    
    
100. 
     Editorial Note: Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of beta-Catenin Signaling.
     PLoS One. 2024;19:e0303600.
     PubMed    
     
     
     
101. BIANCHI F, Le Noci V, Bernardo G, Gagliano N, et al
     Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings.
     PLoS One. 2024;19:e0303875.
     PubMed     Abstract available
     
     
     
102. LUO W, Chang G, Lin D, Xie H, et al
     3,3'-((3,4,5-trifluoropHenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) inhibit lung cancer cell proliferation and migration.
     PLoS One. 2024;19:e0303186.
     PubMed     Abstract available
     
     
     
103. ZHONG J, Hua Y, Zou S, Wang B, et al
     Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway.
     PLoS One. 2024;19:e0299921.
     PubMed     Abstract available
     
     
     
104. BOUKANSA S, Mouhrach I, El Agy F, El Bardai S, et al
     Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report.
     PLoS One. 2024;19:e0298721.
     PubMed     Abstract available
     
     
     
105. PATHAN RK, Shorna IJ, Hossain MS, Khandaker MU, et al
     The efficacy of machine learning models in lung cancer risk prediction with explainability.
     PLoS One. 2024;19:e0305035.
     PubMed     Abstract available
     
     
     
106. CUI R, Li Y, Yu X, Wei C, et al
     Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.
     PLoS One. 2024;19:e0304941.
     PubMed     Abstract available
     
     
     
107. ALSHEHRI MA, Asiri SA, Helmi N, Baeissa HM, et al
     Unrevealing the multitargeted potency of 3-1-BCMIYPPA against lung cancer structural maintenance and suppression proteins through pharmacokinetics, QM-DFT, and multiscale MD simulation studies.
     PLoS One. 2024;19:e0303784.
     PubMed     Abstract available
     
     
     
108. YU H, Wang Y, Yue X, Zhang H, et al
     Influence of the atmospheric environment on spatial variation of lung cancer incidence in China.
     PLoS One. 2024;19:e0305345.
     PubMed     Abstract available
     
     
     
109. JARRY U, Bostoen M, Archambeau J, Pineau R, et al
     Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
     PLoS One. 2024;19:e0304914.
     PubMed     Abstract available
     
     
     
110. WANG C, Zhu X, Zheng M, Chen Y, et al
     Pan-cancer analysis of PSCA that is associated with immune infiltration and affects patient prognosis.
     PLoS One. 2024;19:e0298469.
     PubMed     Abstract available
     
     
     
111. WANG B, Wang J, Sun T, Ding Y, et al
     Lu's approach for video-assisted thoracoscopic surgery.
     PLoS One. 2024;19:e0300632.
     PubMed     Abstract available
     
     
     
112. GONG S, Li G, Li D, Liu Y, et al
     The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases.
     PLoS One. 2024;19:e0305670.
     PubMed     Abstract available
     
     
     
113. 
     Correction: Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter.
     PLoS One. 2024;19:e0306665.
     PubMed     Abstract available
     
     
     
114. USHER-SMITH JA, Masson G, Godoy A, Burge SW, et al
     Acceptability of adding a non-contrast abdominal CT scan to screen for kidney cancer and other abdominal pathology within a community-based CT screening programme for lung cancer: A qualitative study.
     PLoS One. 2024;19:e0300313.
     PubMed     Abstract available
     
     
     
115. PARK J, Rho MJ, Moon MH
     Enhanced deep learning model for precise nodule localization and recurrence risk prediction following curative-intent surgery for lung cancer.
     PLoS One. 2024;19:e0300442.
     PubMed     Abstract available
     
     
     
116. LOTFI F, Rashidian H, Hadji M, Mohebbi E, et al
     Exposure to second-hand smoke and risk of lung cancer among Iranian population: A multicenter case-control study.
     PLoS One. 2024;19:e0306517.
     PubMed     Abstract available
     
     
     
117. HAO H, Maeda Y, Fukazawa T, Yamatsuji T, et al
     Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0307052.
     PubMed     Abstract available
     
     
     
118. VAN DEN BOSSCHE J, De Laere M, Deschepper K, Germonpre P, et al
     Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
     PLoS One. 2024;19:e0307204.
     PubMed     Abstract available
     
     
     
119. ARMIJO N, Salas C, Espinoza N, Espinoza M, et al
     Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system.
     PLoS One. 2024;19:e0307473.
     PubMed     Abstract available
     
     
     
120. CHEN XP, He SX, Chen MY, Chen FB, et al
     Meta-analysis of the accuracy for RASSF1A methylation in bronchial aspirates for the diagnosis of lung cancer.
     PLoS One. 2024;19:e0299447.
     PubMed     Abstract available
     
     
     
121. SIL BK, Jamiruddin MR, Paul PK, Aekwattanaphol N, et al
     Ascorbic acid as serine protease inhibitor in lung cancer cell line and human serum albumin.
     PLoS One. 2024;19:e0303706.
     PubMed     Abstract available
     
     
     
122. LIANG Y, Maeda O, Kondo C, Nishida K, et al
     Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
     PLoS One. 2024;19:e0307580.
     PubMed     Abstract available
     
     
     
123. MATSUMOTO H, Fukushima T, Kobayashi N, Higashino Y, et al
     High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse.
     PLoS One. 2024;19:e0299760.
     PubMed     Abstract available
     
     
     
124. HUMMELINK K, van der Noort V, Muller M, Schouten RD, et al
     Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
     PLoS One. 2024;19:e0293707.
     PubMed     Abstract available
     
     
     
125. KOUHMAREH K, Martin E, Finlay D, Bhadada A, et al
     Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.
     PLoS One. 2024;19:e0306450.
     PubMed     Abstract available
     
     
     
126. SCHOUTEN RD, Schouten I, Schuurbiers MMF, van der Noort V, et al
     Optimising primary molecular profiling in non-small cell lung cancer.
     PLoS One. 2024;19:e0290939.
     PubMed     Abstract available
     
     
     
127. KISS N, Ugalde A, Prado CM, Denehy L, et al
     Living with low muscle mass and its impact throughout curative treatment for lung cancer: A qualitative study.
     PLoS One. 2024;19:e0304003.
     PubMed     Abstract available
     
     
     
128. PETERS HA, Weiss D, Boschheidgen M, Mamlins E, et al
     Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
     PLoS One. 2024;19:e0307998.
     PubMed     Abstract available
     
     
     
129. SAJJADI SF, Salehi N, Sadeghi M
     Comprehensive integrated single-cell RNA sequencing analysis of brain metastasis and glioma microenvironment: Contrasting heterogeneity landscapes.
     PLoS One. 2024;19:e0306220.
     PubMed     Abstract available
     
     
     
130. ITO M, Koido S, Iwamoto T, Morimoto S, et al
     Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.
     PLoS One. 2024;19:e0308330.
     PubMed     Abstract available
     
     
     
131. SARAJI A, Wulf K, Stegmann-Frehse J, Kang D, et al
     Comprehensive transcriptomic analysis of prostate cancer lung metastases.
     PLoS One. 2024;19:e0306525.
     PubMed     Abstract available
     
     
     
132. ANANDAKRISHNAN R, Shahidi R, Dai A, Antony V, et al
     An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations.
     PLoS One. 2024;19:e0307232.
     PubMed     Abstract available
     
     
     
133. MA Y, Li Z, Li D, Zheng B, et al
     G0 arrest gene patterns to predict the prognosis and drug sensitivity of patients with lung adenocarcinoma.
     PLoS One. 2024;19:e0309076.
     PubMed     Abstract available
     
     
     
134. KILDAHL-ANDERSEN A, Hofstad EF, Solberg OV, Sorger H, et al
     Navigated ultrasound bronchoscopy with integrated positron emission tomography-A human feasibility study.
     PLoS One. 2024;19:e0305785.
     PubMed     Abstract available
     
     
     
135. YU SC, Huang JY, Cheng YF, Cheng CY, et al
     Prognostic factors in clinical stage IIIA small cell lung cancer: An analysis of a population-based cancer registry in Taiwan.
     PLoS One. 2024;19:e0297399.
     PubMed     Abstract available
     
     
     
136. LAI GS, Chen CS, Cheng JC, Li JR, et al
     Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
     PLoS One. 2024;19:e0309941.
     PubMed     Abstract available
     
     
     
137. LIN L, Deng L, Bao Y
     Identifying crucial lncRNAs and mRNAs in hypoxia-induced A549 lung cancer cells and investigating their underlying mechanisms via high-throughput sequencing.
     PLoS One. 2024;19:e0307954.
     PubMed     Abstract available
     
     
     
138. 
     Correction: The efficacy of machine learning models in lung cancer risk prediction with explainability.
     PLoS One. 2024;19:e0310604.
     PubMed     Abstract available
     
     
     
139. PIRES DC, Arueira Chaves L, Dantas Cardoso CH, Faria LV, et al
     Effects of low dose computed tomography (LDCT) on lung cancer screening on incidence and mortality in regions with high tuberculosis prevalence: A systematic review.
     PLoS One. 2024;19:e0308106.
     PubMed     Abstract available
     
     
     
140. WU X, Li W, Chen Y
     Differences in the risk association of TERT-CLPTM1L rs4975616 (A>G) with lung cancer between Caucasian and Asian populations: A meta-analysis.
     PLoS One. 2024;19:e0309747.
     PubMed     Abstract available
     
     
     
141. FANIZZI A, Fadda F, Maddalo M, Saponaro S, et al
     Developing an ensemble machine learning study: Insights from a multi-center proof-of-concept study.
     PLoS One. 2024;19:e0303217.
     PubMed     Abstract available
     
     
     
142. GEUBBELMANS M, Claes J, Nijsten K, Gervois P, et al
     Optimization of whole slide imaging scan settings for computer vision using human lung cancer tissue.
     PLoS One. 2024;19:e0309740.
     PubMed     Abstract available
     
     
     
143. KIM T, Choe J, Shin SH, Jeong BH, et al
     Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.
     PLoS One. 2024;19:e0310079.
     PubMed     Abstract available
     
     
     
144. JAIN R, Singh P, Abdelkader M, Boulila W, et al
     Efficient lung cancer detection using computational intelligence and ensemble learning.
     PLoS One. 2024;19:e0310882.
     PubMed     Abstract available
     
     
     
145. DJERIDI Z, Ghouar A, Boulares H, Bouye M, et al
     Applications of the prediction of satisfaction design for monitoring single-arm phase II trials.
     PLoS One. 2024;19:e0305814.
     PubMed     Abstract available
     
     
     
146. HUANG H, Li L, Tong L, Luo H, et al
     Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
     PLoS One. 2024;19:e0310808.
     PubMed     Abstract available
     
     
     
147. XIE J, He Y, Che S, Zhao W, et al
     Differential diagnosis of benign and lung adenocarcinoma presenting as larger solid nodules and masses based on multiscale CT radiomics.
     PLoS One. 2024;19:e0309033.
     PubMed     Abstract available
     
     
     
148. NAGAMINE H, Yashiro M, Mizutani M, Sugimoto A, et al
     Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.
     PLoS One. 2024;19:e0297397.
     PubMed     Abstract available
     
     
     
149. STOVERUD KH, Bouget D, Pedersen A, Leira HO, et al
     AeroPath: An airway segmentation benchmark dataset with challenging pathology and baseline method.
     PLoS One. 2024;19:e0311416.
     PubMed     Abstract available
     
     
     
150. NDUAGUBA SO, Kelly KM
     Multilevel factors associated with delays in screening, diagnosis, and treatment for lung cancer-A mixed methods systematic review protocol.
     PLoS One. 2024;19:e0309196.
     PubMed     Abstract available
     
     
     
151. PENG J, Xu H, Liu Q
     Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
     PLoS One. 2024;19:e0312133.
     PubMed     Abstract available
     
     
     
152. CHEN H, Hu XB, Zhou J, He CY, et al
     Association of chronic obstructive pulmonary disease with risk of lung cancer in individuals aged 40 years and older: A cross-sectional study based on NHANES 2013-2018.
     PLoS One. 2024;19:e0311537.
     PubMed     Abstract available
     
     
     
153. GREGORY MD, Ofosu-Asante K, Lazarte JMS, Puente PE, et al
     Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.
     PLoS One. 2024;19:e0312563.
     PubMed     Abstract available
     
     
     
154. MAHJABEEN A, Hasan MZ, Rahman MT, Islam MA, et al
     Genetic insights into the connection between pulmonary TB and non-communicable diseases: An integrated analysis of shared genes and potential treatment targets.
     PLoS One. 2024;19:e0312072.
     PubMed     Abstract available
     
     
     
155. LV Z, Liu P, Yang Y, Ji J, et al
     (-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2alpha/ATF4 signaling pathway.
     PLoS One. 2024;19:e0313010.
     PubMed     Abstract available
     
     
     
156. SUZUKI S, Yashiro M, Izumi N, Tsukioka T, et al
     Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT.
     PLoS One. 2024;19:e0312846.
     PubMed     Abstract available
     
     
     
157. PAVEL MA, Islam R, Babor SB, Mehadi R, et al
     Non-small cell lung cancer detection through knowledge distillation approach with teaching assistant.
     PLoS One. 2024;19:e0306441.
     PubMed     Abstract available
     
     
     
158. YANG Y, Li J, Wang Y, Luo L, et al
     Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
     PLoS One. 2024;19:e0312605.
     PubMed     Abstract available
     
     
     
159. 
     Retraction: Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0314046.
     PubMed    
     
     
     
160. LIAO Y, Zhou Y, Zhou X, Chen J, et al
     Gastroesophageal reflux disease and risk of incident lung cancer: A large prospective cohort study in UK Biobank.
     PLoS One. 2024;19:e0311758.
     PubMed     Abstract available
     
     
     
161. CAI S, Yang W, Luo H, Li Z, et al
     Clinical features and prognostic factors of IV combined small cell lung cancer: A propensity score matching analysis.
     PLoS One. 2024;19:e0313221.
     PubMed     Abstract available
     
     
     
162. SLOMKA J, Berthou H, Mansuet-Lupo A, Blons H, et al
     Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.
     PLoS One. 2024;19:e0307161.
     PubMed     Abstract available
     
     
     
163. DONG Y, Li S, Che G
     Is it safe and feasible to use multi-lateral-pores drainage strategy after video-assisted thoracoscopic surgery?
     PLoS One. 2024;19:e0313176.
     PubMed     Abstract available
     
     
     
164. BONERT M, Schittenhelm J, Begum H, Lu JQ, et al
     Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.
     PLoS One. 2024;19:e0314205.
     PubMed     Abstract available
     
     
     
165. ZHANG E, Feng X, Liu F, Zhang P, et al
     Correction: Roles of PI3K/Akt and c-Jun Signaling Pathways in Human Papillomavirus Type 16 Oncoprotein-Induced HIF-1alpha, VEGF, and IL-8 Expression and In Vitro Angiogenesis in Non-Small Cell Lung Cancer Cells.
     PLoS One. 2024;19:e0314378.
     PubMed     Abstract available
     
     
     
166. YADAV DP, Sharma B, Webber JL, Mehbodniya A, et al
     EDTNet: A spatial aware attention-based transformer for the pulmonary nodule segmentation.
     PLoS One. 2024;19:e0311080.
     PubMed     Abstract available
     
     
     
167. GUIBIN D, Xiaolan S, Wei Z, Xiaoli L, et al
     Prediction of iodine-125 seed implantation efficacy in lung cancer using an enhanced CT-based nomogram model.
     PLoS One. 2024;19:e0313570.
     PubMed     Abstract available
     
     
     
168. WANG S, Yan H, Wen J, Zhou Z, et al
     Risk factors for conversion to thoracotomy in patients with lung cancer undergoing video-assisted thoracoscopic surgery: A meta-analysis.
     PLoS One. 2024;19:e0313236.
     PubMed     Abstract available
     
     
     
169. ARUNACHALAM A, Sura S, Murphy J, Conkling P, et al
     Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer.
     PLoS One. 2024;19:e0314156.
     PubMed     Abstract available
     
     
     
170. JIANG HN, Zeng B, Zhang Y, Daskoulidou N, et al
     Correction: Involvement of TRPC Channels in Lung Cancer Cell Differentiation and the Correlation Analysis in Human Non-Small Cell Lung Cancer.
     PLoS One. 2024;19:e0315242.
     PubMed     Abstract available
     
     
     
171. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
     Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
     PLoS One. 2024;19:e0315252.
     PubMed     Abstract available
     
     
     
172. JALILIAN H, Heydari S, Javanshir E, Jamebozorgi K, et al
     Hospitalization costs and out-of-pocket (OOP) payment in lung cancer patients in Iran: Health Sector Evolution Plan (HSEP) has reduced OOP payments and improved financial protection.
     PLoS One. 2024;19:e0297934.
     PubMed     Abstract available
     
     
     
173. CHATWICHIEN J, Semakul N, Yimklan S, Suwanwong N, et al
     Lutein derived from Xenostegia tridentata exhibits anticancer activities against A549 lung cancer cells via hyaluronidase inhibition.
     PLoS One. 2024;19:e0315570.
     PubMed     Abstract available
     
     
     
174. YUAN S, Ou W, Mi X, Hou J, et al
     Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways.
     PLoS One. 2024;19:e0310825.
     PubMed     Abstract available
     
     
     
175. KLIMONTOVA M, Zhang H, Campos-Laborie F, Webster N, et al
     THUMPD3 regulates alternative splicing of ECM transcripts in human lung cancer cells and promotes proliferation and migration.
     PLoS One. 2024;19:e0314655.
     PubMed     Abstract available
     
     
     
176. HANAOKA S, Nomura Y, Hayashi N, Sato I, et al
     Deep generative abnormal lesion emphasization validated by nine radiologists and 1000 chest X-rays with lung nodules.
     PLoS One. 2024;19:e0315646.
     PubMed     Abstract available
     
     
     
177. ZHANG H, Liu S, Zhang J, Wang Y, et al
     CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration.
     PLoS One. 2024;19:e0314228.
     PubMed     Abstract available
     
     
     
178. ROMASZKO-WOJTOWICZ A, Doboszynska A, Piechnik A, Kuziemski K, et al
     Impact of the COVID-19 pandemic on lung cancer diagnosis in northern Poland-addressing the COVID-19 debt.
     PLoS One. 2024;19:e0316261.
     PubMed     Abstract available
     
     
     
179. SAIT ARW, AlBalawi E, Nagaraj R
     Ensemble learning driven Kolmogorov-Arnold Networks-based Lung Cancer classification.
     PLoS One. 2024;19:e0313386.
     PubMed     Abstract available
     
     
     
180. SALAZAR P, Cheung P, Ganeshan B, Oikonomou A, et al
     Predefined and data-driven CT radiomics predict recurrence-free and overall survival in patients with pulmonary metastases treated with stereotactic body radiotherapy.
     PLoS One. 2024;19:e0311910.
     PubMed     Abstract available
     
     
     
181. SAETANG M, Kunapaisal T, Wasinwong W, Boonthum P, et al
     Predictors associated with Clavien-Dindo complications in lung cancer surgery: A retrospective cohort study.
     PLoS One. 2024;19:e0316214.
     PubMed     Abstract available
     
     
     
182. DU L, Ren W, Liu L, Zhu H, et al
     SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway.
     PLoS One. 2024;19:e0316432.
     PubMed     Abstract available
     
     
     January 2023
183. LIU Y
     Identification and comprehensive analysis of super-enhancer related genes involved in epithelial-to-mesenchymal transition in lung adenocarcinoma.
     PLoS One. 2023;18:e0291088.
     PubMed     Abstract available
     
     
     
184. ZHOU D, Zhai X, Zhang R
     Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
     PLoS One. 2023;18:e0291461.
     PubMed     Abstract available
     
     
     
185. DAEI SORKHABI A, Fazlollahi A, Sarkesh A, Aletaha R, et al
     Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials.
     PLoS One. 2023;18:e0291044.
     PubMed     Abstract available
     
     
     
186. WU M, Liu S, Wang C, Wu Y, et al
     Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.
     PLoS One. 2023;18:e0291178.
     PubMed     Abstract available
     
     
     
187. LIU Y, Yan M
     Trends in all causes and cause specific mortality attributable to ambient particulate matter pollution in China from 1990 to 2019: A secondary data analysis study.
     PLoS One. 2023;18:e0291262.
     PubMed     Abstract available
     
     
     
188. 
     Retraction: Frondoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and Metastasis.
     PLoS One. 2023;18:e0291478.
     PubMed    
     
     
     
189. FUJIKAWA K, Saito T, Kurose K, Kojima T, et al
     Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
     PLoS One. 2023;18:e0291772.
     PubMed     Abstract available
     
     
     
190. LEROY K, Audigier Valette C, Alexandre J, Boussemart L, et al
     Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
     PLoS One. 2023;18:e0291495.
     PubMed     Abstract available
     
     
     
191. BINGHAM SL, Small S, Semple CJ
     A qualitative evaluation of a multi-modal cancer prehabilitation programme for colorectal, head and neck and lung cancers patients.
     PLoS One. 2023;18:e0277589.
     PubMed     Abstract available
     
     
     
192. IKEMOTO S, Sakurai F, Tokuoka S, Yamashita T, et al
     Novel conditionally replicating adenovirus-mediated efficient detection of circulating tumor cells in lung cancer patients.
     PLoS One. 2023;18:e0286323.
     PubMed     Abstract available
     
     
     
193. WESTEEL V, Schuette W, Urban T, Radonjic D, et al
     Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
     PLoS One. 2023;18:e0292307.
     PubMed     Abstract available
     
     
     
194. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
     Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
     PLoS One. 2023;18:e0294382.
     PubMed     Abstract available
     
     
     
195. MAKRAKIS D, Rounis K, Tsigkas AP, Georgiou A, et al
     Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
     PLoS One. 2023;18:e0294384.
     PubMed     Abstract available
     
     
     
196. PENG B, Ling X, Huang T, Wan J, et al
     HSP70 via HIF-1 alpha SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation.
     PLoS One. 2023;18:e0294263.
     PubMed     Abstract available
     
     
     
197. LIMBU S, McCloskey KE
     Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.
     PLoS One. 2023;18:e0294171.
     PubMed     Abstract available
     
     
     
198. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
     Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
     PLoS One. 2023;18:e0287465.
     PubMed     Abstract available
     
     
     
199. NIBID L, Greco C, Cordelli E, Sabarese G, et al
     Deep pathomics: A new image-based tool for predicting response to treatment in stage III non-small cell lung cancer.
     PLoS One. 2023;18:e0294259.
     PubMed     Abstract available
     
     
     
200. ARBEE-KALIDAS N, Moutlana HJ, Moodley Y, Kebalepile MM, et al
     The association between cardiopulmonary exercise testing and postoperative outcomes in patients with lung cancer undergoing lung resection surgery: A systematic review and meta-analysis.
     PLoS One. 2023;18:e0295430.
     PubMed     Abstract available
     
     
     
201. NEMLANDER E, Rosenblad A, Abedi E, Ekman S, et al
     Correction: Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers.
     PLoS One. 2023;18:e0295780.
     PubMed     Abstract available
     
     
     
202. WANG J, Wang H, Xu J, Song Q, et al
     Identification of protein signatures for lung cancer subtypes based on BPSO method.
     PLoS One. 2023;18:e0294243.
     PubMed     Abstract available
     
     
     
203. WU YY, Shen WB, Li JW, Liu MY, et al
     Targeted metabolomics reveals the association between central carbon metabolism and pulmonary nodules.
     PLoS One. 2023;18:e0295276.
     PubMed     Abstract available
     
     
     
204. 
     Retraction: Restoration of Mal overcomes the defects of apoptosis in lung cancer cells.
     PLoS One. 2023;18:e0296552.
     PubMed    
     
     
     
205. 
     Correction: Nicotine Promotes Tumor Growth and Metastasis in Mouse Models of Lung Cancer.
     PLoS One. 2023;18:e0296477.
     PubMed     Abstract available
     
     
     
206. TIAN W, Guo Q, Fu D, Ma X, et al
     Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials.
     PLoS One. 2023;18:e0295745.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.